← Leaderboards
Mohammad Rashidian
Dana-Farber Cancer Inst
$1,587,857
Attributed
$2,601,885
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $700.7K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,601,885 · 2
By mechanism
R01$2,028,057 · 1
K22$573,828 · 1
Top collaborators
- Erin Wei3 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Shannon J Turley$5,420,711
- Matthew S Davids$2,319,476
- Erin Wei$1,014,029
- Kai W Wucherpfennig$37,935,181
- Kornelia Polyak$28,582,691
Others in their field
Other Emerging Leaders on “Cell Type”
- Evan Z Macosko · Broad Institute, Inc.$36,871,464
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Thomas Denny · Duke University$19,381,749
- Tomasz Nowakowski · University Of California, San Francisco$18,472,946
- Hemali Phatnani · New York University School Of Medicine$18,358,586
- Rui M. Costa · Columbia University Health Sciences$13,762,381
Research focus
Cell TypeAntibodiesAntigensTranslatingProteinsEvaluationEngineeringImmune SystemResponseT-LymphocyteSide EffectSerumAnimalsIn VivoCellsImmunosuppressive AgentsAnti-Tumor Immune ResponseAntigen TargetingAntigen-Specific T CellsBasement MembraneAnimal ModelAffectBaseAutoreactivity
Grant awards (6)
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases$663,019
R01 · FY2025 · AI · contact PI
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases$664,312
R01 · FY2024 · AI · contact PI
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases$700,726
R01 · FY2023 · AI · contact PI
Noninvasive monitoring and evaluation of anti-tumor responses as a predictive tool$191,276
K22 · FY2021 · CA · contact PI
Noninvasive monitoring and evaluation of anti-tumor responses as a predictive tool$191,276
K22 · FY2020 · CA · contact PI
Noninvasive monitoring and evaluation of anti-tumor responses as a predictive tool$191,276
K22 · FY2019 · CA · contact PI